-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320

Benzinga·08/27/2026 12:43:49
Listen to the news
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $320.